Q2 2024 Holdings
Filed 2024-08-13 | 9 holdings | $319.4M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Arcellx, Inc.(ACLX) | Common Stock | 03940C100 | $129.5M | 2,346,630 | 40.5% |
| Crispr Therapeutics AG(CRSP) | Common Shares | H17182108 | $56.7M | 1,048,951 | 17.7% |
| ARS Pharmaceuticals, Inc.(SPRY) | Common Stock | 82835W108 | $34.1M | 4,012,903 | 10.7% |
| Alumis Inc.(ALMS) | Common Stock | 022307102 | $26.1M | 1,959,896 | 8.2% |
| Mineralys Therapeutics Inc.(MLYS) | Common Stock | 603170101 | $23.6M | 2,016,822 | 7.4% |
| Design Therapeutics, Inc.(DSGN) | Common Stock | 25056L103 | $21.9M | 6,526,476 | 6.8% |
| Nkarta, Inc.(NKTX) | Common Stock | 65487U108 | $19.7M | 3,333,333 | 6.2% |
| enGene Holdings Inc.(ENGN) | Common Shares | 29286M105 | $4.7M | 500,000 | 1.5% |
| Kala Bio, Inc.(KALA) | Common Stock | 483119202 | $3.1M | 443,661 | 1.0% |